Compare NREF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | CRBP |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.4M | 202.6M |
| IPO Year | 2020 | N/A |
| Metric | NREF | CRBP |
|---|---|---|
| Price | $14.80 | $10.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.75 | ★ $48.38 |
| AVG Volume (30 Days) | 56.6K | ★ 345.6K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 13.52% | N/A |
| EPS Growth | ★ 132.43 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $151,560,000.00 | N/A |
| Revenue This Year | $27.88 | N/A |
| Revenue Next Year | $5.41 | $220.00 |
| P/E Ratio | $4.81 | ★ N/A |
| Revenue Growth | ★ 107.15 | N/A |
| 52 Week Low | $12.14 | $4.64 |
| 52 Week High | $18.09 | $20.56 |
| Indicator | NREF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 38.89 |
| Support Level | $14.22 | $10.05 |
| Resistance Level | $14.57 | $11.98 |
| Average True Range (ATR) | 0.31 | 0.74 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 96.18 | 27.33 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.